Table 3: Clinical trials for ADPKD.

Start-finish dateInterventionActionDesign

HALT-ADPKD STUDY (NCT00283686)2006–2013ACE inhibitors and ARBs (singly or in combination)Reduce the rate of increase in kidney volume and slow the decline in GFRMulticenter, randomized, placebo controlled
NCT004289482007–2011V2 receptor antagonist (Tolvaptan)Reduce the concentrations of cAMP and slow the progression of renal enlargementMulticenter, double blind, placebo controlled
NCT003092832006–2010Long-acting somatostatin (octreotide)Inhibit the growth of the polycystic kidneys and liverRandomized Single Center, Single blind, Placebo controlled
NCT004261532007–2010 (open-label extention)Long-acting somatostatin (octreotide)Inhibit the growth of the polycystic kidneys and liverDouble blind, Randomized, Placebo controlled, Crossover
NCT005650972007–2009 (open-label extention)Long-acting somatostatin (lanreotide)Inhibit the growth of the polycystic kidneys and liverDouble blind, Randomized, Placebo controlled
Trials with target mTORmTOR inhibitors (sirolimus, everolimus)Modulate disease progression and development of renal cysts